investigations
Last reviewed 09/2021
Possible investigations in possible heart failure include:
- chest radiology
- the ECG - is recommended in every patient with suspected HF (1), may elucidate the cause of heart failure:
- left ventricular hypertrophy which may be caused by chronic hypertension or aortic stenosis
- evidence of ischaemic heart disease
- p-mitrale of mitral stenosis
- echocardiography identifies:
- focal or diffuse myocardial dysfunction
- valvular disease
- pericardial disease
- left ventricular systolic dysfunction
- biochemistry, haematology and urinalysis:
- defines electrolyte disturbances and assesses renal function
- excludes anaemia
- exclude thyrotoxicosis in patients with atrial fibrillation
- excludes causes of oedema such as liver disease, nephrotic syndrome and acute renal failure
- natriuretic
peptides - testing for Brain-type natriuretic peptide (BNP), atrial natriuretic
peptide (ANP), and N-terminal (NT)-ANP has been shown to increase the reliability
of diagnosis of heart failure in primary care
- these peptides are released from ventricular myocytes in response to volume overload (stretch), and their concentration has been shown to an extremely sensitive marker for heart failure
- Other possible investigations include:
- radionuclide ventriculography e.g. MUGA scan
- a myocardial biopsy to obtain histological data
NICE have suggested that investigations chosen in primary care depend on whether there is a past history of myocardial infarction. NICE suggest to (1):
- refer patients with suspected heart failure and previous myocardial infarction
(MI) urgently, to have transthoracic Doppler 2D echocardiography and specialist
assessment within 2 weeks
- measure serum natriuretic peptides (B-type natriuretic peptide [BNP] or
N-terminal pro-B-type natriuretic peptide [NTproBNP]) in patients with suspected
heart failure without previous MI
- because very high levels of serum natriuretic peptides carry a poor prognosis,
refer patients with suspected heart failure and a BNP level above 400 pg/ml
(116 pmol/litre) or an NTproBNP level above 2000 pg/ml (236 pmol/litre) urgently,
to have transthoracic Doppler 2D echocardiography and specialist assessment
within 2 weeks
- refer patients with suspected heart failure and a BNP level between 100
and 400 pg/ml (29-116 pmol/litre) or an NTproBNP level between 400 and 2000
pg/ml (47-236 pmol/litre) to have transthoracic Doppler 2D echocardiography
and specialist assessment within 6 weeks
Perform an ECG in all patients and consider the following tests to evaluate possible aggravating factors and/or alternative diagnoses:
- chest X-ray
- blood tests:
- electrolytes, urea and creatinine - eGFR (estimated glomerular filtration rate)
- thyroid function tests
- liver function tests
- fasting lipids
- fasting glucose
- full blood count
- urinalysis
- peak flow or spirometry
When a diagnosis of heart failure has been made, assess severity, aetiology, precipitating factors, type of cardiac dysfunction and correctable causes
Notes:
- serum natriuretic peptides:
- obesity or treatment with diuretics, angiotensin-converting enzyme (ACE)
inhibitors, beta-blockers, angiotensin II receptor antagonists (ARBs)
and aldosterone antagonists can reduce levels of serum natriuretic peptides
- high levels of serum natriuretic peptides can have causes other than
heart failure (for example, left ventricular hypertrophy, ischaemia, tachycardia,
right ventricular overload, hypoxaemia [including pulmonary embolism],
renal dysfunction [GFR < 60 ml/minute], sepsis, chronic obstructive pulmonary
disease [COPD], diabetes, age > 70 years and cirrhosis of the liver)
- a serum BNP level less than 100 pg/ml (29 pmol/litre) or an NTproBNP
level less than 400 pg/ml (47 pmol/litre) in an untreated patient makes
a diagnosis of heart failure unlikely
- the level of serum natriuretic peptide does not differentiate between heart failure due to left ventricular systolic dysfunction and heart failure with preserved left ventricular ejection fraction
- obesity or treatment with diuretics, angiotensin-converting enzyme (ACE)
inhibitors, beta-blockers, angiotensin II receptor antagonists (ARBs)
and aldosterone antagonists can reduce levels of serum natriuretic peptides
Reference:
- 1) NICE (August 2010). chronic heart failure
- 2) MeReC Bulletin 2008; 18 (3):1-9.
chest radiology in heart failure
echocardiography in heart failure
brain type ( B type BNP ) natriuretic peptide in the detection of congestive heart failure
brain type ( B type BNP ) natriuretic peptide in the detection of acute heart failure